Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CROMOC
- Development stage
- Preclinical
- Lead developer
- RDP Pharma
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
CROMOC is a preclinical-stage anticancer therapeutic being developed by RDP Pharma. It is a biomolecule/polypeptide-based therapy that utilizes a DNA recognition-site specific endonuclease directed at active chromatin as its active ingredient. The drug is equipped with a liver-sorting peptide, known as a Drug Delivery Module (DDM), designed to target liver tissue specifically. The mechanism of action involves cleaving active chromatin in cancer cells to induce cell death. CROMOC is currently in development for the treatment of liver cancer and lung cancer.
02
Targets
DNA
Beyond the preview
Go deeper on CROMOC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CROMOC.